CN104095868A - Medicine composition improving sugar tolerance and pharmacy use of medicine composition - Google Patents
Medicine composition improving sugar tolerance and pharmacy use of medicine composition Download PDFInfo
- Publication number
- CN104095868A CN104095868A CN201410355498.3A CN201410355498A CN104095868A CN 104095868 A CN104095868 A CN 104095868A CN 201410355498 A CN201410355498 A CN 201410355498A CN 104095868 A CN104095868 A CN 104095868A
- Authority
- CN
- China
- Prior art keywords
- glucose
- chrysoeriol
- medicine composition
- glucose glycosides
- tolerance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 15
- 229930182470 glycoside Natural products 0.000 claims description 40
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 2
- GAMYVSCDDLXAQW-MIUGBVLSSA-N 5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=C3C(=O)C=2)=C1 GAMYVSCDDLXAQW-MIUGBVLSSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 10
- 238000003304 gavage Methods 0.000 description 9
- 208000002705 Glucose Intolerance Diseases 0.000 description 8
- 201000009104 prediabetes syndrome Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 7
- 229960003105 metformin Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- SCZVLDHREVKTSH-UHFFFAOYSA-N 4',5,7-trihydroxy-3'-methoxyflavone Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 SCZVLDHREVKTSH-UHFFFAOYSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010054805 Macroangiopathy Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UOSZQIQUCYTISS-UHFFFAOYSA-N chrysoeriol Natural products C1=C(O)C(C)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 UOSZQIQUCYTISS-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- -1 flavone compounds Chemical class 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000055876 Cyanthillium Species 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000977585 Saussurea medusa Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicine composition improving sugar tolerance and pharmacy use of the medicine composition. The composition is prepared by an active ingredient and an auxiliary material; the active ingredient comprises thermopsoside. The medicine can not only reduce body mass, but also improve sugar tolerance, and is suitable for preventing and curing an obesity type diabetes patient and a sugar tolerance reducing patient that has not developed into diabetes yet.
Description
Technical field
The invention belongs to medical technical field, in particular to a kind of pharmaceutical composition and pharmaceutical applications thereof that improves carbohydrate tolerance.
Background technology
Impaired glucose tolerance is an interstage in type Ⅱdiabetes mellitus evolution, and after the several years, these crowd's great majority may develop into diabetes patient, and the incidence rate of impaired glucose tolerance crowd macroangiopathy is also high than general population.Therefore, preventing that impaired glucose tolerance from developing into diabetes, even make it to return to NGT, is important measures that prevent and treat diabetes, is also an important indicator evaluating diabetes control medicine.
The therapeutic intervention of impaired glucose tolerance has non-medication and Drug two aspects.Non-medication comprises diet intervention, and as total amount of heat and fat constituent that dietary restriction is taken in, sugar is drunk, eaten less in restriction, encourages polyphagia containing coarse grain and the fresh vegetables of the trace element such as chromium, magnesium, high fiber food.In addition, among the pharmaceutical intervention treatment multinational positive execution in the Zheng world.Conventional medicine has metformin, thiazolidinediones medicine, alpha-glucosidase inhibitor, sulfonylureas drugs for diabetes etc.If these drug mains are respectively by improving insulin resistant, the glucose that increases patients with impaired glucose tolerance shifts out rate and insulin sensitivity index, and reduces on an empty stomach and insulin level after the meal.By slow down disaccharidase and starch based polysaccharide, change glucose into, thereby the stimulation that reduces postprandial hyperglycemia, alleviates β cell reduces hyperinsulinemia.Yet, existing as the medicines such as metformin be chemicals, be mainly used in diabetics, for the patients with impaired glucose tolerance that not yet develops into diabetes, take these medicines after side effect larger.
Chrysoeriol-7-O-β-D-Glucose glycosides (thermopsoside) is present in several kinds of Chinese medicinal materials, as Saussurea medusa Maxim., Herba Vernoniae Cinereae, etc.CN101474196A discloses separation a kind of herb from ironweed plant Herba Vernoniae Cinereae or root and has obtained a flavonoid active site, and method for making method: utilize chromatographic separation technology separated preparation one class active site from the herb of Herba Vernoniae Cinereae, this active site comprises 7 flavone compounds, respectively: apiolin, chrysoeriol, luteolin, chrysoeriol-7-O-β-D-Glucose glycosides, luteolin-7-O-β-D-Glucose glycosides, Quercetin, apiolin-4 '-O-β-D-Glucose glycosides, this active site is in the news and has the effect of anti-senile dementia.By retrieval domestic and foreign literature, still do not find that chrysoeriol-7-O-β-D-Glucose glycosides has the bioactive bibliographical information of blood sugar lowering or raising carbohydrate tolerance at present.
Summary of the invention
The object of the invention is to by natural drug is studied, a kind of medicine of plant-derived raising carbohydrate tolerance is provided.It is active component that this medicine be take chrysoeriol-7-O-β-D-Glucose glycosides, can be used for not yet developing into the treatment of the patients with impaired glucose tolerance of diabetes.
The object of the present invention is achieved like this:
Improve a pharmaceutical composition for carbohydrate tolerance, by active component and adjuvant, be prepared from, described active component comprises chrysoeriol-7-O-β-D-Glucose glycosides.
Preferably, improve as mentioned above the pharmaceutical composition of carbohydrate tolerance, wherein said active component is comprised of as unique component chrysoeriol-7-O-β-D-Glucose glycosides.
The pharmaceutical composition of raising carbohydrate tolerance of the present invention, wherein chrysoeriol-7-O-β-D-Glucose glycosides has carried out relevant animal experiment as active component in gavage mode, result medicine absorbs significantly through gastrointestinal, and therefore described pharmaceutical composition can be oral formulations.Wherein said oral formulations comprises tablet, capsule, granule.
It should be noted that, according to the common process of formulation art, those skilled in the art is easy to adjuvant available on chrysoeriol-7-O-β-D-Glucose glycosides and pharmaceutics to be prepared into conventional solid orally ingestible, as granule, tablet, capsule.Wherein, on pharmaceutics, available adjuvant comprises filler, disintegrating agent, binding agent, correctives, lubricant etc.
The present invention has studied the impact of chrysoeriol-7-O-β-D-Glucose glycosides on normal mouse blood sugar and exogenous glucose tolerance and body weight by animal experiment.Result of study shows, 10d gavage gives chrysoeriol-7-O-β-D-Glucose glycosides continuously, and the fasting glucose of normal mouse is not made significant difference, effect that may non-stimulated normal insulin secretion.And when a certain amount of exogenous glucose of normal mouse gavage, blood glucose raises rapidly, but the mice that gives in advance chrysoeriol-7-O-β-D-Glucose glycosides can significantly suppress blood sugar increasing, the dosis tolerata that strengthens exogenous glucose, this is significant for prevent diabetes and macroangiopathy.It is likely by reducing body, to absorb speed or the quantity of glucose that chrysoeriol-7-O-β-D-Glucose glycosides improves glucose tolerance in mice, thereby regulates blood glucose.Research also finds that chrysoeriol-7-O-β-D-Glucose glycosides administration group Mice Body quality obviously alleviates than blank group, shows that control has potential effect to chrysoeriol-7-O-β-D-Glucose glycosides to weight.As can be seen here, chrysoeriol-7-O-β-D-Glucose glycosides on the one hand on normal mouse fasting glucose without impact, another aspect can ameliorate body quality can improve carbohydrate tolerance again, this means that chrysoeriol-7-O-β-D-Glucose glycosides can further be developed to medicine or the slimming health food into control obese diabetic.
Based on above result of study, the present invention also provides a kind of pharmaceutical applications, that is: the purposes of chrysoeriol-7-O-β-D-Glucose glycosides in the medicine of preparation raising carbohydrate tolerance; Or: chrysoeriol-7-O-β-D-Glucose glycosides is in the medicine of preparation control obese diabetic or the purposes in health product.
Compared with prior art, the pharmaceutical composition that contains chrysoeriol-7-O-β-D-Glucose glycosides the present invention relates to has following outstanding advantage: (1) can ameliorate body quality can improve carbohydrate tolerance again, the patients with impaired glucose tolerance that is applicable to preventing and treating obese diabetic patient and not yet develops into diabetes; (2) to orthoglycemic crowd without effect, avoided hypoglycemic generation.
The specific embodiment
The present invention has studied the impact of chrysoeriol-7-O-β-D-Glucose glycosides on normal mouse blood sugar and exogenous glucose tolerance and body weight by animal experiment.Result of study shows, 10d gavage gives chrysoeriol-7-O-β-D-Glucose glycosides continuously, and the fasting glucose of normal mouse is not made significant difference, effect that may non-stimulated normal insulin secretion.And when a certain amount of exogenous glucose of normal mouse gavage, blood glucose raises rapidly, but the mice that gives in advance chrysoeriol-7-O-β-D-Glucose glycosides can significantly suppress blood sugar increasing, strengthens the dosis tolerata of exogenous glucose.The present invention also finds that chrysoeriol-7-O-β-D-Glucose glycosides administration group Mice Body quality obviously alleviates than blank group, shows that control has potential effect to chrysoeriol-7-O-β-D-Glucose glycosides to weight.Following examples are concrete processs of the test:
The affect experimental study of embodiment 1 chrysoeriol-7-O-β-D-Glucose glycosides on normal mouse blood sugar
Kunming mouse, clean level, male and female half and half, weight (20 ± 2g), be divided at random blank group, positive controls (glibenclamide 400mg/kg), test high and low (chrysoeriol-7-O-β-D-Glucose glycosides 260,130mg/kg) dosage group, 12 every group.Each administration group gavage every day 1 time, blank group gives equal-volume distilled water (20m1/kg), continuously 10d.Before last administration, water 12h is can't help in mice fasting, and 1 h after last administration, gets blood from eye socket rear vein beard, and separation of serum is measured blood glucose value by the explanation of glucose oxidase method test kit.
Result of the test by table 1 can find out, after normal mouse administration 10d, positive drug glibenclamide can significantly reduce mouse blood sugar (
p< 0.05), and chrysoeriol-7-O-β-D-Glucose glycosides high and low dose does not have a significant effect to mouse blood sugar.
Table 1 is respectively organized mouse blood sugar value comparison (mmol/L)
With the comparison of blank group,
* p< 0.05.
The affect experimental study of embodiment 2 chrysoeriols-7-O-β-D-Glucose glycosides on normal glucose tolerance in mice and weight
Kunming mouse, clean level, male and female half and half, weight (20 ± 2g), be divided at random blank group, model control group, positive controls (metformin group 750mg/kg), test high and low (chrysoeriol-7-O-β-D-Glucose glycosides 260,130mg/kg) dosage group, 12 every group.Each administration group gavage every day 1 time, blank group and model control group give equal-volume distilled water (20m1/kg), continuously 10d.Before last administration, water 12h is can't help in mice fasting, each is organized mice and claims weight, after last administration 1 h, except blank group gavage distilled water, all the other respectively organize equal gavage glucose solution (2.5g/kg), respectively at before filling sugar (being 0h blood glucose), fill with sugar rear 30min, lh and 2h, from mouse orbit rear vein beard, get blood, separation of serum, measures blood glucose value by the explanation of glucose oxidase method test kit.
Result of the test by table 2 can find out, each organize mouse stomach and give glucose after blood glucose start to raise, to 0.5h, reach summit.With model control group contrast, positive drug metformin and chrysoeriol-7-O-β-D-Glucose glycosides high and low dose to glucose cause hyperglycemia and have the inhibitory action of highly significant (
p< 0.05 or
p< 0.01).After lh, the blood sugar reducing function highly significant of metformin and chrysoeriol-7-O-β-D-Glucose glycosides high dose (
p< 0.01), low dosage have obvious blood sugar reducing function (
p< 0.05).After 2h, chrysoeriol-7-O-β-D-Glucose glycosides high dose still have highly significant blood sugar reducing function (
p< 0.01), be better than metformin.
Table 2 is respectively organized glucose tolerance in mice comparison (mmol/L)
With model control group comparison,
★ p< 0.05,
★ ★ p< 0.01.
Result of the test by table 3 can find out, after normal mouse administration 10d, positive drug metformin and chrysoeriol-7-O-β-D-Glucose glycosides can significantly reduce Mice Body quality (
p< 0.05 or
p< 0.01), especially the chrysoeriol of high dose-7-O-β-D-Glucose glycosides effect is more obvious.
Table 3 is respectively organized Mice Body mass ratio (g)
With model control group comparison,
★ p< 0.05,
★ ★ p< 0.01.
Claims (6)
1. improve a pharmaceutical composition for carbohydrate tolerance, by active component and adjuvant, be prepared from, it is characterized in that: described active component comprises chrysoeriol-7-O-β-D-Glucose glycosides.
2. improve according to claim 1 the pharmaceutical composition of carbohydrate tolerance, it is characterized in that: described active component is comprised of as unique component chrysoeriol-7-O-β-D-Glucose glycosides.
3. according to the pharmaceutical composition that improves carbohydrate tolerance described in claim 1 or 2, it is characterized in that: described pharmaceutical composition is oral formulations.
4. improve according to claim 3 the pharmaceutical composition of carbohydrate tolerance, it is characterized in that: described oral formulations is tablet, capsule or granule.
5. chrysoeriol-7-O-β-D-Glucose glycosides improves the purposes in the medicine of carbohydrate tolerance in preparation.
6. chrysoeriol-7-O-β-D-Glucose glycosides is in the medicine of preparation control obese diabetic or the purposes in health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410355498.3A CN104095868B (en) | 2014-07-25 | 2014-07-25 | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410355498.3A CN104095868B (en) | 2014-07-25 | 2014-07-25 | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104095868A true CN104095868A (en) | 2014-10-15 |
| CN104095868B CN104095868B (en) | 2016-06-01 |
Family
ID=51664663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410355498.3A Active CN104095868B (en) | 2014-07-25 | 2014-07-25 | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104095868B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816473A (en) * | 2015-07-06 | 2016-08-03 | 武汉华纳联合药业有限公司 | Flavonoid glycoside composition, preparation and production method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474196A (en) * | 2009-02-17 | 2009-07-08 | 南京中医药大学 | Flavone active site of Vernonia cinerea as well as preparation method and use thereof |
-
2014
- 2014-07-25 CN CN201410355498.3A patent/CN104095868B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474196A (en) * | 2009-02-17 | 2009-07-08 | 南京中医药大学 | Flavone active site of Vernonia cinerea as well as preparation method and use thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816473A (en) * | 2015-07-06 | 2016-08-03 | 武汉华纳联合药业有限公司 | Flavonoid glycoside composition, preparation and production method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104095868B (en) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101735151B1 (en) | Anti-fatigue composition, formulation and use thereof | |
| JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| CN104740425B (en) | A kind of pharmaceutical composition for treating rheumatic Bi syndrome and its production and use | |
| CN105395677A (en) | Royal jelly, propolis and Chinese magnoliavine fruit capsule and preparation method thereof | |
| CN104840962B (en) | A kind of pharmaceutical composition for improving high fat high-carbonhydrate diet complication and its application | |
| CN104095868A (en) | Medicine composition improving sugar tolerance and pharmacy use of medicine composition | |
| CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN101884723B (en) | Anemarrhena and goldthread composition preparation used for treating diabetes and preparation method thereof | |
| CN104223073A (en) | Food, health-care product or pharmaceutical composition for sleep aiding | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN103720808B (en) | A kind of composition and use thereof, preparation method with relieving constipation effect | |
| JP2010168399A (en) | Pharmaceutical for controlling elevation of blood sugar | |
| CN106420697A (en) | Polymethoxylated flavone, composition and application of polymethoxylated flavone preparation in preventing or treating diabetes | |
| CN102225082B (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN104758772A (en) | Japanese galangal flower extract for improving sugar tolerance and usage of Japanese galangal flower extract | |
| CN104027450B (en) | A kind of Chinese medicine composition for the treatment of diabetes | |
| CN103766453A (en) | Yam corn biscuit with health care effect on diabetes | |
| CN109430721A (en) | A kind of wheat embryo composition and preparation method thereof with hypoglycemic effect | |
| CN102579947A (en) | Chinese medicinal composition and preparation method thereof | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN100363000C (en) | Chinese and western medicines composition contg. Avandia and its prepn. method | |
| CN101791350B (en) | Glibenclamide-containing traditional Chinese and western medicine composition | |
| CN101791351B (en) | Glipizide-containing traditional Chinese and western medicine composition | |
| CN101757253B (en) | Traditional Chinese medicine and Western medicine composition containing gliquidone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yuling Inventor after: Huang Jinhua Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160429 Address after: 264003 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant after: YANTAI HUAWEN XINXIN PHARMACEUTICAL Co.,Ltd. Applicant after: Wang Yuling Applicant after: Huang Jinhua Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Applicant before: Wang Xueyan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160713 Address after: 264003 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Patentee after: YANTAI HUAWEN XINXIN PHARMACEUTICAL Co.,Ltd. Address before: 264003 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Patentee before: YANTAI HUAWEN XINXIN PHARMACEUTICAL Co.,Ltd. Patentee before: Wang Yuling Patentee before: Huang Jinhua |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170524 Address after: 226000, 9 Jiangsu Road, Binjiang fine chemical industry zone, Nantong, Jiangsu, Qidong Patentee after: NANTONG FINC PHARMACEUTICAL CHEMICAL Co.,Ltd. Address before: 264003 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Patentee before: YANTAI HUAWEN XINXIN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP03 | Change of name, title or address |
Address after: 226000, No.78 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong City, Nantong City, Jiangsu Province Patentee after: Nantong Fayink High-tech Material Technology Co.,Ltd. Address before: 226000 9 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong, Nantong, Jiangsu Patentee before: NANTONG FINC PHARMACEUTICAL CHEMICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231227 Address after: 226000 Qidong Binjiang fine chemical industry park, Nantong City, Jiangsu Province Patentee after: Qidong Binhua water supply Co.,Ltd. Address before: 226000, No.78 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong City, Nantong City, Jiangsu Province Patentee before: Nantong Fayink High-tech Material Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |